COSMOS Pharmaceutical Corporation (TYO: 3349)
Japan
· Delayed Price · Currency is JPY 7,456.00
-154.00 (-2.02%)
Jan 20, 2025, 3:30 PM JST
COSMOS Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Nov '24 Nov 30, 2024 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 | May '20 May 31, 2020 | 2019 - 2015 |
| Revenue | 994,495 | 964,989 | 827,697 | 755,414 | 726,424 | 684,403 | Upgrade
|
| Revenue Growth (YoY) | 10.49% | 16.59% | 9.57% | 3.99% | 6.14% | 11.99% | Upgrade
|
| Cost of Revenue | 793,047 | 776,683 | 658,979 | 603,966 | 581,313 | 549,419 | Upgrade
|
| Gross Profit | 201,448 | 188,306 | 168,718 | 151,448 | 145,111 | 134,984 | Upgrade
|
| Selling, General & Admin | 147,172 | 138,536 | 122,807 | 107,756 | 99,163 | 93,347 | Upgrade
|
| Operating Expenses | 165,440 | 156,804 | 138,589 | 121,651 | 111,964 | 105,890 | Upgrade
|
| Operating Income | 36,008 | 31,502 | 30,129 | 29,797 | 33,147 | 29,094 | Upgrade
|
| Interest Expense | -161 | -99 | -51 | -52 | -60 | -69 | Upgrade
|
| Interest & Investment Income | 45 | 44 | 47 | 52 | 57 | 65 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,839 | 2,852 | 2,960 | 3,063 | 2,690 | 2,473 | Upgrade
|
| EBT Excluding Unusual Items | 38,731 | 34,299 | 33,085 | 32,860 | 35,834 | 31,563 | Upgrade
|
| Gain (Loss) on Sale of Assets | 75 | 75 | - | 265 | 4,190 | - | Upgrade
|
| Asset Writedown | -1,237 | -1,010 | -113 | -70 | -31 | -47 | Upgrade
|
| Other Unusual Items | 380 | 355 | -200 | -8 | -1,398 | -1,114 | Upgrade
|
| Pretax Income | 37,949 | 33,719 | 32,772 | 33,047 | 38,595 | 30,402 | Upgrade
|
| Income Tax Expense | 10,654 | 9,265 | 8,975 | 9,892 | 11,439 | 8,967 | Upgrade
|
| Net Income | 27,295 | 24,454 | 23,797 | 23,155 | 27,156 | 21,435 | Upgrade
|
| Net Income to Common | 27,295 | 24,454 | 23,797 | 23,155 | 27,156 | 21,435 | Upgrade
|
| Net Income Growth | 13.33% | 2.76% | 2.77% | -14.73% | 26.69% | 11.73% | Upgrade
|
| Shares Outstanding (Basic) | 79 | 79 | 79 | 79 | 79 | 79 | Upgrade
|
| Shares Outstanding (Diluted) | 79 | 79 | 79 | 79 | 79 | 79 | Upgrade
|
| Shares Change (YoY) | 0.06% | 0.05% | -0.00% | -0.00% | -0.00% | - | Upgrade
|
| EPS (Basic) | 344.38 | 308.61 | 300.48 | 292.37 | 342.89 | 270.65 | Upgrade
|
| EPS (Diluted) | 344.38 | 308.61 | 300.48 | 292.37 | 342.89 | 270.65 | Upgrade
|
| EPS Growth | 13.26% | 2.71% | 2.77% | -14.73% | 26.69% | 11.73% | Upgrade
|
| Free Cash Flow | 3,535 | -635 | 7,798 | -11,303 | 1,811 | 39,513 | Upgrade
|
| Free Cash Flow Per Share | 44.60 | -8.01 | 98.46 | -142.72 | 22.87 | 498.91 | Upgrade
|
| Dividend Per Share | 30.000 | 60.000 | 50.000 | 40.000 | 35.000 | 27.500 | Upgrade
|
| Dividend Growth | -48.94% | 20.00% | 25.00% | 14.29% | 27.27% | 10.00% | Upgrade
|
| Gross Margin | 20.26% | 19.51% | 20.38% | 20.05% | 19.98% | 19.72% | Upgrade
|
| Operating Margin | 3.62% | 3.26% | 3.64% | 3.94% | 4.56% | 4.25% | Upgrade
|
| Profit Margin | 2.74% | 2.53% | 2.88% | 3.07% | 3.74% | 3.13% | Upgrade
|
| Free Cash Flow Margin | 0.36% | -0.07% | 0.94% | -1.50% | 0.25% | 5.77% | Upgrade
|
| EBITDA | 57,110 | 51,426 | 47,497 | 44,907 | 46,932 | 42,656 | Upgrade
|
| EBITDA Margin | 5.74% | 5.33% | 5.74% | 5.94% | 6.46% | 6.23% | Upgrade
|
| D&A For EBITDA | 21,102 | 19,924 | 17,368 | 15,110 | 13,785 | 13,562 | Upgrade
|
| EBIT | 36,008 | 31,502 | 30,129 | 29,797 | 33,147 | 29,094 | Upgrade
|
| EBIT Margin | 3.62% | 3.26% | 3.64% | 3.94% | 4.56% | 4.25% | Upgrade
|
| Effective Tax Rate | 28.07% | 27.48% | 27.39% | 29.93% | 29.64% | 29.49% | Upgrade
|
| Advertising Expenses | - | 1,812 | 1,648 | 1,632 | 2,784 | 4,266 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.